“PRECISION: Multi-center, blinded, randomized, PaRallEl-group, Phase 3 study with aproCItentan in Subjects with resIstant hypertension (RHT).” A research study to show the effect of aprocitentan in the treatment of difficult to control (resistant) high blood pressure (hypertension) and find out more about its safety.

Last updated: N/A
Sponsor: N/A
Overall Status: Active - Recruiting

Phase

3

Condition

High Blood Pressure (Hypertension)

Treatment

N/A

Clinical Study ID

TX216576
  • Ages 18-100
  • All Genders

Study Summary

The purpose of the study is to show that aprocitentan, a new study drug, can lower the blood pressure of subjects with difficult to control (resistant) high blood pressure (hypertension) and keep the reduction for long period of time. The purpose is also to see if aprocitentan is safe for people with difficult to control (resistant) blood pressure (hypertension).

Eligibility Criteria

Inclusion

  • Currently taking 3 or more medications against high blood pressure (anti hypertensives) , but your blood pressure is still high.
  • Systolic blood pressure > 140 mmHg
  • Male and female subject; 18 years or older
  • Documentation in medical records of difficult to control (resistant hypertension)

Study Design

Study Start date:
Estimated Completion Date:

Study Description

  • The possible benefits you may have from being in the study include a reduction of your blood pressure as reported from the previous study with aprocitentan in 327 subjects with high blood pressure.
  • Your general health and the status of your disease (high blood pressure) will be monitored very closely during your participation in the study (up to 17 months).
  • You will receive a set stipend to cover time and travel.
  • All tests, medication and procedures related to the research study will be paid for by the study i.e EKG, blood work, study medication.